Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine for Opioid Withdrawal in the ER
NCT03489161Phase 1Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Aug 2018
- Primary completion
- Aug 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buprenorphine in opioid withdrawal, sponsored by Virginia Commonwealth University. Primary endpoints: Recruitment rates and Acceptability of transferral to outpatient clinic (MOTIVATE) at 48 hours. Started Aug 2018; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid withdrawal
Beyond the preview
Go deeper on NCT03489161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03489161.